Biohaven Pharmaceutical Holding EBITDA Margin 2016-2022 | BHVN

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Biohaven Pharmaceutical Holding (BHVN) over the last 10 years. The current EBITDA margin for Biohaven Pharmaceutical Holding as of March 31, 2022 is .
Biohaven Pharmaceutical Holding EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2022-03-31 $0.74B $-0.50B -67.48%
2021-12-31 $0.46B $-0.68B -146.87%
2021-09-30 $0.31B $-0.70B -226.30%
2021-06-30 $0.19B $-0.72B -380.53%
2021-03-31 $0.11B $-0.72B -669.16%
2020-12-31 $0.06B $-0.64B -993.75%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.111B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00